New VentureWise program on COPD and asthma
28 July 2016
A new agreement between GlaxoSmithKline (GSK) and VentureWise—part of the MedicineWise Group—will see an independent educational program delivered to GPs on the topic of chronic obstructive pulmonary disease (COPD).
VentureWise Managing Director Greg Hughes says the new GSK-funded program aims to to provide greater clarity to health professionals on medicine choice for COPD, improve adherence and inhaler technique, and reduce confusion associated with medicines for COPD and asthma.
“This agreement provides an opportunity for both parties to contribute to the enhancement of medical knowledge and improving quality use of medicines,” says Mr Hughes.
As part of the agreement, VentureWise retains complete independence in determining all aspects of the design, content and implementation of the program, ensuring it remains an independent, quality GP education program,” he says.
“VentureWise has commissioned resources from within the MedicineWise Group to design, develop and deliver the education program.”
GSK introduced a new framework at the start of 2016 for its medical education and interactions with healthcare professionals to increase transparency. The grant to VentureWise has been made under GSK’s initiative to support third-party independent medical education conducted fully at arms-length.
“VentureWise and GSK independently recognise that there are challenges for GPs in keeping up with advances in COPD therapeutics, given the recent proliferation in options and in the evidence base,” says GSK Australia Medical Director Dr Andrew Weekes.
“GSK’s recent commitment to supporting independent medical education around such identified gaps gave us the opportunity to support this important programme. Our new funding framework guarantees the independence of this education, developed and delivered entirely at arm’s length from GSK. We believe this model has the potential to make a meaningful difference for patients in Australian primary care,” Dr Weekes says.
Educational visits commenced this month in selected locations around Australia.
For more information about VentureWise, go to www.venturewise.com.au. For more information about GSK’s independent medical education initiative go to http://au.gsk.com/en-au/responsibility/independent-medical-education/.
Media enquiries, VentureWise: Greg Millard, 0432 781 178
Media enquiries, GSK: Bernadette Murdoch, 0449 950 745
VentureWise is an independently run, wholly owned subsidiary of NPS MedicineWise. The work of VentureWise remains consistent with the mission of NPS MedicineWise to help people make the best decisions about medicines and other health choices.
GlaxoSmithKline is a global research-based pharmaceutical and healthcare company. Since 1886 GSK has delivered the highest quality medicines, vaccines and over-the-counter healthcare products to Australians while investing in local research and providing skilled jobs. For further information please visit www.au.gsk.com.